This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Pennant Group, Inc. (PNTG) Meets Q2 Earnings Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of 0% and 2.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aveanna Healthcare (AVAH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Aveanna (AVAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Encompass Health (EHC) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of -8.25% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Hanger (HNGR) Stock Jumps 25%: Will It Continue to Soar?
by Zacks Equity Research
Hanger (HNGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LifeStance Health (LFST) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
LifeStance Health (LFST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Pennant Group, Inc. (PNTG) Stock Jumps 6%: Will It Continue to Soar?
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aveanna Healthcare (AVAH) Q1 Earnings Lag Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of -33.33% and 4.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 2.86% and 0.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.97% and 2.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AlerisLife (ALR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Star (ALR) delivered earnings and revenue surprises of -181.82% and 6.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Aveanna (AVAH)? Wall Street Analysts Think 86%
by Zacks Equity Research
The consensus price target hints at an 85.6% upside potential for Aveanna (AVAH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AVAH vs. ELAN: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVAH vs. ELAN: Which Stock Is the Better Value Option?